ANN ARBOR, Mich., April 5 /PRNewswire/ -- Ann Arbor-based Genetics Squared, Inc., announced today the addition of Dr. Franco M. Muggia and Dr. Anthony W. Tolcher to its scientific advisory board. The scientific advisory board provides Genetics Squared management with expert advice on the future scientific direction of the industry as well as scientific and medical opportunities for the company.
"Genetics Squared is truly fortunate to welcome two internationally recognized experts in clinical oncology and investigational drug development to its scientific advisory board," said Dr. Peter Lenehan, Genetics Squared's chief medical officer. "Genetics Squared looks forward to their active involvement in identifying promising compounds for in-licensing and ways to expedite their development."
Franco M. Muggia, M.D.
Dr. Muggia is the Anne Murnick & David H. Cogan professor of oncology and director of the Division of Medical Oncology at the New York University School of Medicine. He is an internationally recognized expert and innovator in the early clinical development of novel anticancer compounds. Dr. Muggia is a strong advocate for, and is actively engaged in, performing correlative laboratory studies using patient-derived samples to assist in elucidating the mechanisms of action of these novel agents and to guide the development of future clinical trials.
Dr. Muggia is also the editor of the Spanish edition of the Journal of Clinical Oncology and leads the Adult Treatment Editorial Board for the NCI's PDQ (Physician Data Query) comprehensive cancer database.
"A number of anticancer drugs deserve another look," said Dr. Muggia. "Genetics Squared offers the possibility of scientifically mining neglected chemical and biological entities using current laboratory and clinical tools."
Dr. Muggia added, "From the fresh perspective of mechanistic discoveries, we are learning increasing aspects of the biology of neoplasia and what contributes to the selectivity of drugs for cancer versus normal tissues. This knowledge undoubtedly leads to better selection of patients for treatment, and also ways of minimizing toxicity. Having studied camptothecin in 1969, and seeing the resurgence of interest in this drug and its derivatives after the discovery of their target, topoisomerase I, I am confident that among previously studied and discarded anticancer drugs lie many future possibilities."
Anthony W. Tolcher, M.D., FRCP(C)
Dr. Tolcher is the director of clinical research and The John E. Freeman, M.D. Chair for Clinical Research at The Institute for Drug Development, Cancer Therapy & Research Center. He is also a clinical professor of medicine in the Division of Medical Oncology at The University of Texas Health Science Center at San Antonio. Dr. Tolcher's major interest is in the development of new anticancer agents with a special interest in molecular genetic targets for cancer therapy.
He was a Fogarty Fellow at the National Institute of Health and received the Murray Muirhead Award for humanitarian and academic excellence and the Goel Prize in Medicine for excellence in clinical disciplines.
"Genetics Squared is an exciting company and I am delighted to join its SAB," said Dr. Tolcher. "It is clear that cancer is an enormously complex disease and our current understanding is still quite limited. But there is also a great deal of excellent science and terrific therapies that are simply waiting to find the right patients. I believe Genetics Squared has an excellent opportunity with its unique analytical technology to identify and characterize the patients for these promising therapies."
Dr. Muggia and Dr. Tolcher join on the scientific advisory board, Dr. Richard Cote, chairman of the scientific advisory board and professor of pathology and urology at the University of Southern California Keck School of Medicine, Norris Comprehensive Cancer Center; Dr. David W. Fry, chief science officer at Genetics Squared; and Phillip L.C. Banks, director, biostatistical research and consulting for I3 STATPROBE.
About Genetics Squared
Founded in 2002, Genetics Squared is an emerging biotechnology company focused on delivering the promise of personalized medicine. Using its patented evolutionary drug development(TM) technology and methods, Genetics Squared is able to "rescue" promising, but struggling compounds from clinical and market failure. The company's novel analytical approach discovers profiles of therapeutic responders and non-responders or those most likely to experience serious adverse events based on medical history, patient demographics, genetic and protein biomarkers. This allows the company and its service clients to target these promising therapies at the patients most likely to benefit. For more information, please visit http://www.genetics2.com/ .
Genetics Squared, Inc.